Plasma cystatin C and neutrophil gelatinase-associated lipocalin in relation to coronary atherosclerosis on intravascular ultrasound and cardiovascular outcome: Impact of kidney function (ATHEROREMO-IVUS study)

Milos Brankovica, K. Martijn Akkerhuisa, Nermina Buljubasica, Jin M. Chenga, Rohit M. Oemrawsingha, b, Hector M. Garcia-Garciaa, Evelyn Regara, Patrick W. Serruysa, Robert-Jan van Geunsa, Eric Boersmaa, Isabella Kardysa,*

a Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands
b Netherlands Heart Institute, Utrecht, The Netherlands

Article info
Article history:
Received 9 May 2016
Received in revised form 12 September 2016
Accepted 14 September 2016
Available online 17 September 2016

Keywords:
Atherosclerosis
Intravascular ultrasound
Cystatin C
NGAL
Kidney function

Abstract
Background and aims: We investigated whether plasma cystatin C (CysC) and neutrophil gelatinase-associated lipocalin (NGAL) are associated with intravascular ultrasound (IVUS)-derived characteristics of coronary atherosclerosis and 1-year adverse coronary events in patients with normal and mildly-to-moderately impaired kidney function.

Methods: Between 2008 and 2011, virtual histology (VH)-IVUS of a non-culprit coronary artery was performed in 581 patients undergoing coronary angiography. Creatinine, CysC and NGAL were measured in pre-procedural blood samples. Presence of VH-IVUS-derived thin-cap fibroatheroma (TCFA) lesions, lesions with plaque burden (PB) ≥ 70% and lesions with minimal luminal area (MLA) ≤ 4 mm² was assessed. Major adverse coronary events (MACE) comprised the composite of all-cause mortality, acute coronary syndrome, or unplanned coronary revascularization. Analyses were stratified using eGFRCr of 90 ml/min/1.73 m² as the cut-off.

Results: In patients with normal kidney function, those with higher CysC levels had fewer lesions with PB ≥ 70% and fewer VH-TCFA lesions (adjusted odds ratios (ORs) and 95% confidence intervals (CIs): 0.46 [0.30–0.69] and 0.59 [0.44–0.83], respectively, per standard deviation (SD) ln[ng/mL] CysC). Those with higher NGAL levels also had fewer lesions with PB ≥ 70% (adjusted OR [95% CI]: 0.49 [0.29–0.82]). In patients with impaired kidneys, no differences in high-risk lesions were observed for CysC or NGAL. However, those with higher CysC had higher risk of MACE (hazard ratio (HR): 1.4, 95% CI [1.03–1.92]). This was not the case in patients with normal kidney function. NGAL did not influence risk of MACE.

Conclusions: Mild-to-moderate kidney dysfunction modifies the relationship between CysC and high-risk coronary lesions. This has not been established before, and offers an explanation for the difference in findings between experimental and epidemiologic studies.

1. Introduction
Kidney impairment, as assessed by creatinine-based equations of glomerular filtration rate (eGFRCr), is associated with cardiovascular disease independently of established cardiovascular risk factors [1]. In persons with mild kidney dysfunction (eGFRCr in the range of 60–89 ml/min/1.73 m²), cystatin C (CysC) may outperform eGFRCr as a predictor of adverse outcome. This is illustrated by the fact that CysC displays a linear association with mortality in patients with such mild GFR reduction, while eGFRCr has a J-shaped association with mortality, and risk only starts to rise when eGFRCr falls beneath 60 ml/min/1.73 m² [2,3]. Although some studies have shown linear associations of eGFRCr with adverse outcome, these associations were linear only in particular ranges of eGFRCr.
(specifically, eGFR Cr, above 60) [4].

CysC is a cysteine protease inhibitor produced by most nucleated cells, and can be detected in serum or plasma [5]. In *in vitro* and animal experiments, a reduction of CysC correlated with increased activity of cysteine proteases cathepsins K and S, which led to breakdown of the elastic lamina in the blood vessel wall [6]. Altered CysC expression has been identified in diseases which progress by extracellular proteolysis, such as atherosclerosis and aortic aneurysms, and metastasis [7,8]. These experiments, pointing towards a favourable role for CysC, do not concur with the positive associations of CysC with adverse outcomes found in epidemiological studies. Studies on the *in-vivo* association between plasma CysC and coronary atherosclerosis may provide further insight into this discrepancy, but have not yet been performed.

Neutrophil gelatinase-associated lipocalin (NGAL) is a clinically relevant biomarker in acute kidney injury [9] due to its marked increase in plasma and urine after tubulo-interstitial kidney damage [10]. Recently, overexpression of plasma NGAL has been found in coronary plaques, where NGAL inhibits elimination of matrix metalloproteinase-9 (MMP-9) [11,12]. MMP-9 is involved in extracellular matrix degradation, herewith increasing the risk of plaque rupture [13]. NGAL and NGAL/MMP-9 complex have been shown to predict major adverse cardiovascular events in epidemiological studies [14,15].

In spite of the above-described associations that have been demonstrated between CysC, NGAL and adverse cardiac events, the presence and shape of a relationship between plasma CysC, NGAL, and coronary atherosclerosis have not yet been investigated in-vivo. To the best of our knowledge, we are the first to perform such an investigation, and to herewith provide a link between fundamental experiments and epidemiological studies. Specifically, our study aimed to investigate whether plasma CysC and NGAL are associated with IVUS-derived characteristics of *in-vivo* coronary atherosclerosis and 1-year adverse coronary events in patients with normal and mildly-to-moderately impaired kidney function.

2. Materials and methods

2.1. Study population

We have previously described the design of The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound (ATHEROREMIVOUS) [16]. In this study, we included 581 patients undergoing diagnostic coronary angiography or percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) or stable angina pectoris (SAP) between 2008 and 2011 in the Erasmus MC, Rotterdam, the Netherlands. Following coronary angiography, intravascular ultrasound (IVUS) of a non-culprit coronary artery was performed. The human research ethics committee of Erasmus MC, Rotterdam, the Netherlands has approved this study. All included patients have signed informed consent, and the study protocol conformed to the Declaration of Helsinki. This study is registered in ClinicalTrials.gov (number: NCT01789411).

2.2. Kidney function assessment

Estimated Glomerular Filtration Rate (eGFR Cr) was assessed by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [17]. Patients were categorized according to eGFR by using the modified definition from the National Kidney Foundation – Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice guidelines [18]: normal (GFR ≥ 90 ml/min/1.73 m²), mild (GFR 60–89 ml/min/1.73 m²), moderate (GFR 30–59 ml/min/1.73 m²), and severe (GFR 15–29 ml/min/1.73 m²) kidney dysfunction, and kidney failure (GFR<15 ml/min/1.73 m²). No patients with kidney failure were present in this study, and only one patient had eGFR Cr <30 ml/min/1.73 m². The latter was excluded from further analyses. Patients were stratified into those with normal kidney function and those with mildly-to-moderately impaired kidney function, using an eGFR Cr of 90 ml/min/1.73 m² as the cut-off value.

2.3. Biomarkers

Arterial blood was taken before the procedure and stored at −80 °C within 2 h. Samples were available in 570 patients. An immununoturbidimetric high sensitivity assay (Roche Diagnostics Ltd., Rotkreuz, Switzerland) on the Roche Cobas 8000 modular analyser platform was used in the Erasmus MC clinical laboratory to measure the level of C-reactive protein (CRP) in serum samples. The plasma EDTA samples were transported at a temperature of −80 °C to Myriad RBM, Austin, Texas, USA, where cystatin C and NGAL concentrations were assessed by a validated multiplex assay (Custom Human Map, Myriad RBM, Austin, Texas, USA). As a result of the batch-wise handling of the samples, with an update of the composition of the multiplex assay by the manufacturer in-between two batches, cystatin C was measured in the full cohort of 570 patients, and NGAL in a random subset of 473 patients. Both laboratories were blinded to clinical and imaging data.

2.4. Grayscale and radiofrequency intravascular ultrasound (IVUS)

Following coronary angiography, we performed IVUS imaging of the most proximal part of a non-culprit, non-treated coronary vessel. The non-culprit vessel was selected based on the following order: left anterior descending artery; right coronary artery; left circumflex artery. We obtained all IVUS data by the Volcano s5/s5i Imaging System (Volcano Corp., San Diego, CA, USA) using a Volcano-Eagle-Eye Gold IVUS catheter of 20 MHz with an automatic pullback system and a standard pullback speed of 0.5 mm/s. Subsequently, an independent core laboratory (Cardialysis BV, Rotterdam, the Netherlands) analysed IVUS images offline, blinded for clinical and biomarker data. The IVUS virtual histology (IVUS-VH) was assessed by pcVH 2.1 and qVH (Volcano Corp., San Diego, CA, USA) software. In each frame, the external elastic membrane and luminal borders were outlined (median interslice distance, 0.40 mm).

The degree (plaque volume and plaque burden) and composition of the atherosclerotic plaque were assessed. Plaque volume was defined as the total volume of the external elastic membrane occupied by atheroma [19]. Plaque burden was defined as the plaque and media cross-sectional area divided by the external elastic membrane cross-sectional area and is presented as a percentage (Fig. 1). A coronary lesion was defined as a segment with a plaque burden of more than 40% in at least three consecutive frames [16]. The composition of the atherosclerotic plaque was characterized into fibrous, fibro-fatty, dense calcium and necrotic core [20]. Subsequently, three types of VH-IVUS high-risk lesions were identified: 1. Thin-cap fibroatheroma (TCFA) lesion: a lesion with the presence of >10% confluent necrotic core in direct contact with the lumen; 2. A lesion with a plaque burden of >70%; 3. a lesion with a minimal luminal area (MLA) of ≤4.0 mm² [21].

2.5. Follow-up

Clinical follow-up started at inclusion and lasted one year. The
The primary clinical endpoint - MACE - was the composite of all-cause mortality, ACS, or unplanned coronary revascularization. ACS was defined as the clinical diagnosis of ST-segment elevation myocardial infarction (STEMI), non-STEMI, or unstable angina pectoris using the guidelines of the European Society of Cardiology [22,23]. Unplanned coronary revascularizations were defined as unplanned coronary artery bypass grafting or repeat percutaneous coronary intervention. The secondary endpoint was the composite of all-cause mortality or ACS. The endpoints were adjudicated by a clinical event committee blinded for biomarker and IVUS data.

2.6. Statistical analysis

The Kolmogorov-Smirnov test was used to test distributions of continuous variables for normality. CysC and CRP were not normally distributed and were ln-transformed for further analyses. Categorical variables are presented as numbers and percentages. Continuous variables that were normally distributed are presented as mean ± standard deviation (SD); non-normally distributed continuous variables are presented as median and interquartile range (IQR). For reasons of uniformity, all biomarkers are presented as median (IQR).

We examined the associations of plasma CysC and NGAL levels with plaque burden, plaque volume, and the presence of high-risk coronary lesions. Plaque volume was normalized for the imaged segment length. We used linear regression and logistic regression analyses with continuous ln-transformed CysC and NGAL concentrations consecutively as independent variables. To assess the effect of kidney function, we included interaction terms (ln-transformed CysC or NGAL, respectively, with dichotomized eGFRCr (above or below 90 ml/min/1.73 m²)) into the logistic regression models. Subsequently, we stratified all analyses on eGFRCr of 90 ml/min/1.73 m². To test whether effect estimates differed between patients with ACS and patients with SAP, Z-tests for heterogeneity were performed.

Cox proportional hazards regression analyses were performed to evaluate the associations between CysC and NGAL and the clinical study endpoints.

Age, gender, indication for coronary angiography, diabetes mellitus, hypertension, and CRP concentration were considered as potential confounders, and were therefore entered into the multivariable linear and logistic regression models. Multivariable adjustment of Cox proportional hazards models was constrained due to the number of clinical endpoints, and was therefore performed in two steps. For MACE, in the first step the adjustment included age, gender, and indication for angiography; in the second
Finally, we determined the cut-off values of CysC and NGAL that indicate the maximum of Scr/\(C_0\) for a statistically significant difference in plasma NGAL levels between ACS and SAP patients (for the total population, \(p = 0.03\)).

3. Results

3.1. Baseline characteristics

Mean age was 61.6 ± 11.4 years, 75.7% were men, 54.6% had ACS, and 45.4% had SAP (Table 1). The imaged coronary segment had a median length of 44.3 (33.8–55.4) mm. A total of 239 (41.5%) patients had at least one TCFA lesion, 120 (21.0%) had lesions with PB ≥ 70%, and 175 (30.7%) had lesions with MLA ≤ 4 mm². Median eGFR\(_{Cr}\) was 90 (77–98) ml/min/1.73 mm² in the full cohort with similar values in the subset of ACS patients (91[78–100] ml/min/1.73 mm²).

### Table 1

Baseline characteristics.

| Variable characteristics | Total (n = 570) | ACS patients (n = 309) | SAP patients (n = 261) |
|---------------------------|----------------|-----------------------|------------------------|
| **Patient characteristics** |                |                       |                        |
| Age, years (mean ± SD)    | 61.5 ± 11.4    | 59.7 ± 11.9           | 63.6 ± 10.3            |
| Men, n (%)                | 430 (75.4)     | 227 (73.5)            | 203 (77.8)             |
| Diabetes mellitus, n (%)  | 99 (17.4)      | 40 (12.9)             | 59 (22.6)              |
| Hypertension, n (%)       | 295 (51.8)     | 134 (43.4)            | 161 (61.7)             |
| Hypercholesterolemia, n (%) | 317 (55.6)   | 137 (44.3)            | 180 (69.0)             |
| Smoking, n (%)            | 164 (28.8)     | 157 (37.2)            | 49 (18.8)              |
| Positive family history, n (%) | 293 (51.5)  | 140 (45.5)            | 153 (58.6)             |
| Previous MI, n (%)        | 184 (32.3)     | 80 (25.9)             | 104 (39.8)             |
| Previous PCI, n (%)       | 185 (32.5)     | 57 (18.4)             | 128 (49.0)             |
| Previous CABG, n (%)      | 18 (3.2)       | 7 (2.3)               | 11 (4.2)               |
| Previous stroke, n (%)    | 23 (4.0)       | 10 (3.2)              | 13 (5.0)               |
| Peripheral artery disease, n (%) | 36 (6.3)   | 12 (3.9)              | 24 (9.2)               |
| History of heart failure, n (%) | 19 (3.3)   | 6 (1.9)               | 13 (5.0)               |
| **Coronary artery disease** |                |                       |                        |
| No significant stenosis, n (%) | 42 (7.4)    | 18 (5.8)              | 24 (9.2)               |
| 1-vessel disease, n (%)   | 301 (52.8)     | 168 (54.5)            | 133 (51.0)             |
| 2-vessel disease, n (%)   | 166 (29.1)     | 88 (28.5)             | 78 (29.9)              |
| 3-vessel disease, n (%)   | 61 (10.7)      | 35 (11.3)             | 26 (10.0)              |
| PCI performed, n (%)      | 501 (87.9)     | 287 (92.9)            | 214 (82.0)             |
| **IVUS characteristics** |                |                       |                        |
| Segment length (mm), median (IQR) | 44.2 (33.7–55.4) | 43.9 (32.9–54.1) | 44.8 (34.2–57.2) |
| Plaque burden (%), median (IQR) | 39.2 (29.4–46.4) | 37.2 (28.0–45.5) | 40.1 (31.8–47.7) |
| Presence of VH-TCFA, n (%) | 239 (41.9)    | 140 (45.5)            | 99 (37.9)              |
| Presence of PB ≥ 70%, n (%) | 120 (21.0)    | 56 (18.1)             | 64 (24.5)              |
| Presence of MLA ≤ 4 mm² | 175 (30.7)     | 87 (28.2)             | 88 (33.7)              |
| **Renal function** |                |                       |                        |
| eGFR (ml/min/1.73 m²), median (IQR) | 90 (77–98)   | 91 (78–100)           | 89 (77–97)             |
| KDOQI classification, n (%) |                |                       |                        |
| GFR > 90 ml/min/1.73 m² | 291 (51.8)     | 165 (54.3)            | 126 (48.8)             |
| GFR 60–89 ml/min/1.73 m² | 231 (41.1)     | 115 (37.8)            | 116 (45.0)             |
| GFR 30–59 ml/min/1.73 m² | 39 (6.9)       | 23 (7.6)              | 16 (6.2)               |
| GFR < 30 ml/min/1.73 m² | 1 (0.1)        | 1 (0.3)               | 0 (0.0)                |
| **Serum biomarkers** |                |                       |                        |
| NGAL (ng/mL), median (IQR) | 197.0 (143.0–254.0) | 204.0 (148.2–274.5) | 177.0 (141.5–239.0) |
| eGFR\(_{Cr}\) ≥ 90 ml/min/1.73 m² | 183.0 (143.0–227.0) | 193.0 (143.0–243.0) | 174.0 (125.0–223.0) |
| eGFR\(_{Cr}\) 30–89 ml/min/1.73 m² | 216.0 (148.0–293.2) | 228.5 (149.0–307.0) | 197.0 (143.5–257.7) |
| Cystatin C (ng/mL), median (IQR) | 796.0 (691.0–923.0) | 791.0 (674.5–915.5) | 802.0 (712.5–935.5) |
| eGFR\(_{Cr}\) 90–99 ml/min/1.73 m² | 732.0 (644.0–834.0) | 729.0 (637.5–841.5) | 734.5 (650.7–822.5) |
| eGFR\(_{Cr}\) 30–89 ml/min/1.73 m² | 872.0 (775.7–1032.5) | 863.0 (745.0–1040.0) | 879.0 (781.0–1030.0) |
| Creatinine (umol/L), median (IQR) | 77 (66–86) | 77 (65–877) | 76 (67–86) |
| C-reactive protein (mg/L), median (IQR) | 2.1 (0.8–5.3) | 2.8 (1.1–6.9) | 1.4 (0.6–3.1) |

ACS, acute coronary syndrome; SAP, stable angina pectoris; CABG, coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention; CKD, chronic kidney disease; NGAL, neutrophil gelatinase-associated lipocalin; PB, plaque burden; MLA, minimal luminal area.

\(^a\) Significant stenosis was defined as a stenosis >50% of the vessel diameter by visual assessment on the coronary angiogram.

\(^b\) Estimated Glomerular Filtration Rate (eGFR\(_{Cr}\)) using CKD-EPI equation: GFR = 141 × min(Scr/k, 1) × max(Scr/1, 1) × 0.993Age × 1.018 [if female] × 1.159 [if black] where Scr is serum creatinine in mg/dL, k is 0.7 for females and 0.9 for males, \(n\) is –0.329 for females and –0.411 for males, min indicates the minimum of Scr or 1, and max indicates the maximum of Scr/k or 1.

\(^c\) Creatinine available in 99%, total n = 562, ACS n = 304, SAP n = 258.

\(^d\) Measurable in sample of total n = 473, ACS n = 257, SAP n = 216.

\(^e\) A statistically significant difference in plasma NGAL levels between ACS and SAP patients (for total population, \(p = 0.002\); if eGFR\(_{Cr}\) ≥ 90 ml/min/1.73 m², \(p = 0.01\); if eGFR\(_{Cr}\) 30–89 ml/min/1.73 m², \(p = 0.03\)).
3.2. Cystatin C, NGAL and degree of atherosclerosis on grayscale IVUS

Numbers of lesions with plaque burden (PB) ≥70% and minimal luminal area (MLA) ≤4 mm² according to categories of kidney function are depicted in supplementary Fig. 3. Significant interactions were found between CysC and eGFRCr in crude (p = 0.007) and multivariable (p = 0.010) models predicting lesions with PB ≥ 70%. In patients with normal kidney function, those with higher CysC had lower risk of lesions with PB ≥ 70% (per SD increase in ln-transformed CysC: OR [95% CI]: 0.69 [0.39–0.82], p = 0.002) (Table 2, Fig. 1A, C, Supplementary Fig. 1). After multivariable adjustment including CRP levels, risk remained significantly lower (adjusted OR [95% CI]: 0.46 [0.30–0.69], p < 0.001). A CysC level of 773.0 ng/ml was the optimal cut-off value to identify patients who did not have lesions with PB ≥70% (CysC ≥773.0 ng/ml) (Supplementary Fig. 4). Conversely, in patients with mild-to-moderate kidney dysfunction risk did not differ significantly according to CysC levels (adjusted OR [95% CI]: 0.83 [0.69–1.05], p = 0.042) and multivariable (p = 0.002) models predicting lesions with PB ≥70% (Table 2). Risk of lesions with MLA ≤4 mm² was not different for patients with higher CysC or NGAL (Table 2).

Overall, no differences could be demonstrated between CysC and NGAL in either plaque burden or normalized plaque volume of the entirely imaged segment (Table 3 and Supplementary Table 2). Nevertheless, CysC showed a trend towards lower normalized segment plaque volume (per SD increase in ln-transformed CysC: β [95% CI]: –0.43 [–1.02–0.16], p = 0.16) in patients with normal kidney function; whereas no differences were observed in patients with mild-to-moderate kidney dysfunction.

There was no heterogeneity between ACS and SAP patients regarding the differences in IVUS grayscale parameters according to CysC or NGAL levels.

3.3. Cystatin C, NGAL and composition of atherosclerosis on radiofrequency VH-IVUS

Numbers of thin-cap fibroatheroma lesions (VH-TCFAs) according to categories of kidney function are depicted in supplementary Fig. 3. Significant interactions were found between CysC and eGFRCr in crude (p = 0.002) and multivariable (p = 0.003) models predicting VH-TCFAs. In patients with normal kidney function, those with higher CysC levels had lower risk of VH-TCFA lesions (per SD increase in ln-transformed CysC: β [95% CI]: –0.43 [–1.02–0.16], p = 0.16) in patients with normal kidney function; whereas no differences were observed in patients with mild-to-moderate kidney dysfunction.

Table 3 Plasma cystatin C, NGAL and segment characteristics (degree of atherosclerosis: plaque volume and plaque burden; composition of coronary atherosclerosis: 4 components) as determined by VH-IVUS stratified according to kidney function (eGFRCr).

| eGFRCr ≤ 90 ml/min/1.73 m² | Cystatin C¹ | NGAL¹ |
|----------------------------|------------|-------|
| Plaque burden¹ | β coefficient (95% CI) | p | β coefficient (95% CI) | p |
| Plaque volume¹ | -0.02 (–0.16–0.12) | 0.77 | -0.05 (–0.18–0.09) | 0.50 |
| Fl (%)¹ | 0.52 (–1.11–2.15) | 0.53 | 0.60 (–0.98–2.19) | 0.45 |
| FF (%)¹ | 0.03 (–1.10–0.17) | 0.65 | 0.12 (–0.02–0.25) | 0.09 |
| NC (%)² | -0.65 (–1.84–0.53) | 0.28 | -0.85 (–2.00–0.30) | 0.15 |
| DC (%)² | 0.00 (–0.17–0.17) | 0.99 | -0.12 (–0.28–0.04) | 0.15 |
| eGFRCr, 30–89 ml/min/1.73 m² | 0.00 (–0.11–0.12) | 0.94 | -0.03 (–0.15–0.09) | 0.66 |
| Plaque burden¹ | 0.16 (–0.37–0.68) | 0.55 | 0.00 (–0.59–0.51) | 0.89 |
| Plaque volume¹ | -1.04 (–2.45–0.37) | 0.15 | 0.60 (–0.89–2.09) | 0.42 |
| Fl (%)¹ | -0.02 (–0.13–0.10) | 0.76 | -0.01 (–0.12–0.11) | 0.92 |
| FF (%)¹ | -0.44 (–0.47–1.35) | 0.34 | -0.27 (–1.23–0.68) | 0.57 |
| DC (%)² | 0.11 (–0.04–0.25) | 0.15 | -0.06 (–0.21–0.05) | 0.44 |

Fl, fibrous; FF, fibro-fatty; NC, necrotic core; DC, dense calcium.

A Square root transformed.
B Unadjusted β coefficient per standard deviation increase in ln-transformed cystatin C with 95% confidence interval (CI).
C Unadjusted β coefficient per standard deviation increase in NGAL with 95% confidence interval (CI).

a Odds ratio (OR) per standard deviation increase in ln-transformed cystatin C with 95% confidence interval (CI).
b Odds ratio (OR) per standard deviation increase in NGAL with 95% confidence interval (CI); Multivariable model: adjusted for age, gender, diabetes mellitus, hypertension, indication for angiography, C-reactive protein.

Table 2 Plasma cystatin C, NGAL and presence of thin-cap fibroatheroma (VH-TCFA) lesions, lesions with plaque burden (PB) ≥70% and lesions with minimal luminal area (MLA) ≤4 mm² stratified according to kidney function (eGFRCr).
3.4. Cystatin C, NGAL and 1-year MACE

Vital status was acquired for 569 (99.8%) patients. During the 1-year follow-up, 56 patients experienced the primary endpoint (MACE; Supplementary Fig. 3), and 30 patients endured the secondary composite endpoint of all-cause mortality or ACS. In the full cohort, patients with higher CysC had higher risk of MACE (per SD increase in ln-transformed CysC: HR [95% CI]: 1.41 [1.10–1.79], p = 0.006) (Fig. 2, Supplementary Fig. 2). After multivariable adjustment, the risk estimate lost statistical significance. For NGAL, significant differences in risk of MACE were not found (Fig. 2, Supplementary Fig. 2).

In patients with normal kidney function, those with higher CysC levels did not have higher risk of MACE. (Fig. 2, Supplementary Fig. 2). In patients with mild-to-moderate kidney dysfunction, those with higher CysC levels had higher risk of MACE in univariable analysis (HR [95% CI]: 1.40 [1.03–1.92], p = 0.03) (Fig. 2, Supplementary Fig. 2). In multivariable analysis, the HR lost statistical significance, but did not materially change (HR [95% CI]: 1.31 [0.92–1.87], p = 0.12).

Both in the total population and in patients with mild-to-moderate kidney dysfunction, a CysC of 849.0 ng/ml was the optimal cut-off value to identify patients who developed MACE (CysC ≥849.0 ng/ml) (Supplementary Fig. 7).

Patterns of risk of the secondary endpoint (all-cause mortality and ACS) according to CysC and NGAL levels were similar to those of MACE (Supplementary Table 3).

Finally, stratification on the indication for angiography confirmed the risk patterns which were found in the full cohort (Supplementary Table 4).

4. Discussion

We found that in patients with normal kidney function, those with higher CysC levels had fewer high-risk coronary lesions (VH-TCFA and lesions with PB ≥70%), while risk of MACE was not different. Conversely, when kidney function was mildly-to-moderately impaired, no differences in high-risk lesions were observed, but those with higher CysC levels had higher risk of MACE. Therefore, with regard to prediction of cardiovascular risk, CysC appears to carry potential only when eGFRcr is below 90 ml/min/1.73 m². Furthermore, patients with higher NGAL levels had fewer lesions with PB ≥70%, but only when they had normal kidney function. No differences in MACE were found for NGAL, and thus its use for cardiovascular risk prediction could not be substantiated. Altogether, our results on CysC suggest novel pathophysiological insights, because they offer an explanation for the difference in findings observed in experimental and epidemiologic studies so far, and imply that the association between CysC and cardiovascular disease may not be solely explained through its correlation with GFR.

Higher CysC levels have been associated with occurrence of cardiovascular events in various epidemiological studies [25]. Conversely, animal experiments suggest that higher CysC may be favourable. Atherosclerotic mice deficient in CysC display increased plaque size and macrophage content, increased elastic lamina degradation and accumulation of smooth muscle cells [26,61]. Studies in humans have also found reduced CysC in atherosclerotic and aneurysmatic aortic lesions [7]. Xu et al. have demonstrated that immune cells (CD8+ dendritic cells (DC) and macrophages), which are involved in atherosclerotic processes, are major contributors to the circulating CysC pool [27,28]. However, besides a correlation with GFR, the mechanisms that may explain the link between CysC and cardiovascular disease are still unclear. Our study provides additional insights. We found that in patients with normal kidney function, those with higher CysC levels had fewer high-risk coronary lesions, and did not have higher risk of MACE. This is in accordance with a potential ‘athero-protective’ effect.

Conversely, in patients with mild-to-moderate kidney dysfunction, differences in high-risk lesions according to CysC level were not present. This could possibly be explained by the changes in CysC physiology that occur in impaired kidneys. When kidney function deteriorates, circulating plasma CysC increases and oxidative stress advances, both of which stimulate Cys to form homodimers [28,29]. When CysC forms homodimers, it cannot inhibit cysteine proteases, because the inhibitory region is hidden within the dimer interface. Thus, it may no longer be able to exhibit ‘athero-protective’ properties [30]. Although these hypotheses are compelling, additional clinical and experimental studies are necessary to further substantiate the effect modification by kidney function that we observed.

Our findings suggest that NGAL may act on coronary artery disease through a different mechanism than currently investigated. A potential lack of predictive precision due to a limited number of MACE may explain the difference between the current results and previous studies [15,31]. On the other hand, a recent meta-analysis that investigated NGAL as a predictor of cardiovascular disease concluded that strong evidence for independent predictive value of NGAL is still lacking [32]. Notably, we found higher plasma NGAL levels in ACS patients compared to SAP patients, independently of kidney function. This could possibly be explained by neutrophilia as a consequence of more severe cardiac damage in ACS patients compared to SAP patients [33]. However, no heterogeneity between ACS and SAP patients was observed in the relationship between NGAL and IVUS-features of coronary atherosclerosis.

Fig. 2. Plasma cystatin C, NGAL and occurrence of the 1-year MACE. MACE, major adverse coronary event; Hazard ratio (HR) per standard deviation increase in ln-transformed cystatin C and per standard deviation increase in NGAL with 95% confidence interval (CI). *unadjusted model; ① adjusted for age, gender, indication for angiography; ② adjusted for age, gender, indication for angiography, diabetes mellitus, hypertension, C-reactive protein; multivariable adjustment was constrained by the limited number of clinical endpoints.
Some limitations of this study merit consideration. This study is currently the largest cohort in which the associations between IVUS plaque characteristics, CysC and NGAL were investigated. Yet, we cannot exclude the possibility of a chance finding with regard to effect modification by kidney function. However, both the cut-off value (based on K/DOQI guidelines) and the study population (no kidney failure/eGFR <30) were chosen a priori. Still, our findings should be considered hypothesis-generating and warrant external validation. Second, kidney function was determined by the creatinine-based CKD-EPI formula, without direct measurement of GFR. Although the CKD-EPI formula has displayed better performance than the Modification of Diet in Renal Disease (MDRD) equation [17], it is still possible that a few patients are misclassified. Third, VH-IVUS imaging was limited to a pre-specified target segment of a non-culprit coronary artery. This study design was chosen based on the hypothesis that such a non-stenotic segment reflects coronary wall pathophysiology of the larger coronary tree [34,35]. This hypothesis, on its part, was based on ex-vivo, as well as in-vivo studies using IVUS in patients with myocardial infarction. These studies have demonstrated the presence of TFCA in places other than the culprit lesion or even culprit artery [16,36]. In fact, we were subsequently able to confirm this hypothesis, by demonstrating that imaging characteristics of the non-culprit artery are associated with increased risk of MACE within the current study population [34]. Therefore, this study design allows us to investigate whether the patient’s burden and vulnerability of atherosclerotic disease — as reflected by the phenotype of a non-culprit artery segment — is associated with blood biomarkers [16]. Finally, although the spatial resolution of IVUS-VH is formally too low to detect thin caps, we have demonstrated that VH-IVUS derived TFCA lesions strongly and independently predict the occurrence of MACE within the current study population [34].

In conclusion, this study provides new insights into the role of plasma CysC and NGAL in coronary atherosclerosis. Most importantly, it shows that in patients with normal kidney function, those with higher CysC levels have fewer high-risk coronary lesions, while in patients with impaired kidneys, those with higher CysC have higher risk of MACE. Thus, this study implies that mild-to-moderate kidney dysfunction modifies the relationship between plasma CysC and coronary artery disease. This has not been established before, and it offers an explanation for the difference in findings observed in experimental and epidemiologic studies. With regard to cardiovascular risk prediction, CysC showed predictive capacities when eGFRc was below 90 ml/min/1.73 m², whereas NGAL levels were not predictive of MACE.

Conflicts of interest

The authors declared they do not have anything to disclose regarding conflict of interest with respect to this manuscript.

Financial support

This work was supported by the European Commission, Seventh Framework Programme (FP7-HEALTH-2007-2.4.2-1), BMRRI-NL (a research infrastructure financed by the Dutch government, NWO 184.021.007) and the Netherlands Heart Foundation (NHS2009B091 to J.M.C. and NHS2007B012 to R.M.O.)

Acknowledgments

We would like to thank the following interventional cardiologists and technical staff for their contribution to this study: Eric Duckers, MD, PhD; Willem van der Giessen, MD, PhD; Peter P.T. de Jaegere, MD, PhD; Jurgen M.R. Ligthart; Nicolas M.D.A. van Mieghem, MD, PhD; Carl Schultz, MD, PhD; Karen T. Witberg and Felix Zijlstra, MD, PhD.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.atherosclerosis.2016.09.016.

References

[1] J. Redon, L. Cea-Calvo, J.V. Lozano, et al., Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. J. Hypertens. 24 (2006) 663–669.
[2] M.G. Shlipak, R. Katz, M.J. Sarnak, et al., Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann. Intern Med. 145 (2006) 237–246.
[3] C. Chronic Kidney Disease Prognosis, K. Matsuhashi, M. van der Velde, et al., Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis, Lancet 375 (2010) 2071–2081.
[4] Y. Arbel, A. Halkin, A. Finkelstein, et al., Impact of estimated glomerular filtration rate on vascular disease extent and adverse cardiovascular events in patients without chronic kidney disease. Can. J. Cardiol. 29 (2013) 1374–1381.
[5] M.G. Shlipak, M.L. Pradhan, M.J. Sarnak, Update on Cystatin C: new insights into the importance of mild kidney dysfunction, Curr. Opin. Nephrol. Hypert. 15 (2006) 270–275.
[6] G.K. Sukhova, B. Wang, P. Libby, et al., Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice, Circ. Res. 96 (2005) 368–375.
[7] G.P. Shi, G.K. Sukhova, A. Grubb, et al., Cystatin C deficiency in human atherosclerosis and aortic aneurysms, J. Clin. Investig. 104 (1999) 1191–1197.
[8] D. Keppler, Towards novel anti-cancer strategies based on cystatin function, Cancer Lett. 235 (2006) 159–176.
[9] P. Devarajan, NGAL in acute kidney injury: from serendipity to utility, Am. J. Kidney Dis. 52 (2008) 295–300.
[10] K.M. Schmidt-Ott, K. Meri, A. Kalandadze, et al., Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia, Curr. Opin. Nephrol. Hypert. 15 (2006) 442–449.
[11] A.L. van der Heem Dahl, A. Gabrielsen, C.Y. Zhu, et al., Expression of neutrophil gelatine-associated lipocalin in atherosclerosis and myocardial infarction, Arter. Throm. Vas. 26 (2009) 136–142.
[12] L. Yan, N. Borregaard, L. Kjeldsen, et al., The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatine-associated lipocalin (NGAL) - modulation of MMP-9 activity by NGAL, J. Biol. Chem. 276 (2001) 37258–37265.
[13] Z.S. Galis, J.J. Khatri, Matrix metalloproteinases in vascular remodeling and atherogenesis - the good, the bad, and the ugly, Circ. Res. 90 (2002) 251–262.
[14] L.B. Daniels, E. Barrett-Connor, P. Clopton, et al., Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults the rancho bernardo study, J. Am. Coll. Cardiol. 59 (2012) 1101–1109.
[15] J.M. Cheng, K.M. Akherkis, O. Meilhac, et al., Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-Year major adverse cardio-vascular events after coronary angiography, Arter. Thromb.Vasc. 34 (2014) 1078–1084.
[16] S.P.M. de Boer, J.M. Cheng, H.M. Garcia-Garcia, et al., Relation of genetic profile and novel circulating biomarkers with coronary plaque phenotype as determined by intravascular ultrasound: rationale and design of the ATHEROEMO-IVUS study, Eurointervention 10 (2014) 953–960.
[17] A.S. Levey, L.A. Stevens, Estimating GFR using the CKD Epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions, Am. J. Kidney Dis. 53 (2009) 622–627.
[18] F. National Kidney, K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, Am. J. Kidney Dis. 39 (2002) S1–S275.
[19] H.M. Garcia-Garcia, M.A. Costa, P.W. Serruys, Imaging of coronary atherosclerosis - the good, the bad and the ugly, Eur. Heart J. 33 (2012) 2569–2610.
[20] A. Nair, M.P. Margolis, B.D. Kuhn, et al., Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation, Eurointeervention 3 (2007) 113–120.
[21] G.A. Rodriguez-Granillo, H.M. Garcia-Garcia, E.P. Mc Fadden, et al., In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis, J. Am. Coll. Cardiol. 46 (2005) 2038–2042.
[22] Task Force on the management of, STEMI/ESoc P.G. Steg, S.K. James, et al., ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation, Eur. Heart J. 33 (2012) 2569–2610.
[23] C.W. Hamm, J.P. Bassand, S. AgeWall, et al., ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment
elevation of the European Society of Cardiology (ESC), Eur. Heart J. 32 (2011) 2999–3054.

[24] E.F. Schisterman, N.J. Perkins, A. Liu, et al., Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples, Epidemiology 16 (2005) 73–81.

[25] N. Taglieri, W. Koenig, J.C. Kaski, Cystatin C and cardiovascular risk, Clin. Chem. 55 (2009) 1932–1943.

[26] E. Bengtsson, F. To, K. Hakansson, et al., Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice, Arter. Thromb. Vasc. 25 (2005) 2151–2156.

[27] E. Galkina, K. Ley, Immune and inflammatory mechanisms of atherosclerosis (*), Annu. Rev. Immunol. 27 (2009) 165–197.

[28] Y.K. Xu, P. Lindemann, J. Vega-Ramos, et al., Developmental regulation of synthesis and dimerization of the amyloidogenic protease inhibitor cystatin C in the hematopoietic system (*), J. Biol. Chem. 289 (2014) 9730–9740.

[29] G. Zalba, A. Fortuno, J. Diez, Oxidative stress and atherosclerosis in early chronic kidney disease, Nephrol. Dial. Transpl. 21 (2006) 2686–2690.

[30] R. Janowski, M. Kozak, E. Jankowska, et al., Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping, Nat. Struct. Biol. 8 (2001) 316–320.

[31] S. Lindberg, S.H. Pedersen, R. Mogelvang, et al., Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention, J. Am. Coll. Cardiol. 60 (2012) 339–345.

[32] D.N. Cruz, S. Gao, A. Maisel, et al., Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systematic review, Clin. Chem. Lab. Med. 50 (2012) 1533–1545.

[33] A. Sahinarslan, S.A. Kocaman, D. Bas, et al., Plasma neutrophil gelatinase-associated lipocalin levels in acute myocardial infarction and stable coronary artery disease, Coron. Artery Dis. 22 (2011) 333–338.

[34] J.M. Cheng, H.M. Garcia-Garcia, S.P.M. de Boer, et al., In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study, Eur. Heart J. 35 (2014) 630–647.

[35] S.J. Nichols, A. Hsu, K. Wolski, et al., Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome, J. Am. Coll. Cardiol. 55 (2010) 2399–2407.

[36] P. Libby, Atherosclerosis: disease biology affecting the coronary vasculature, Am. J. Cardiol. 98 (2006) 3Q–9Q.